



Dissecting Signalling Contributions of the Alpha and Beta Subunits of the GM-CSF Receptor

Michelle Perugini, B. Med. Pharm. Biotech. (Hons.)

December, 2006

*A thesis submitted for the degree of Doctor of Philosophy in the
School of Medicine at the University of Adelaide*

Declaration

I declare that this thesis contains no material which has been accepted for the award of any other degree or diploma in any university and that, to the best of my knowledge and belief, the thesis contains no material previously published or written by another person, except where due reference is made in the text of the thesis.

I consent to the thesis being made available for photocopying and loan if accepted for the award of the degree.

Michelle Perugini

December 2006

Acknowledgements

I would like to thank all of the staff and students at the Child Health Research Institute where this research was undertaken. The continuous scientific and non-scientific dialogue was useful and greatly appreciated. Thanks also to the University of Adelaide for their financial support and resources.

A special thankyou to my supervisor Richard D'Andrea who has provided continuous support, encouragement, and scientific advice throughout my project. I am very grateful for your help and for making my PhD such an enjoyable experience. I would also like to thank my co-supervisor Tom Gonda for his helpful discussions and meetings throughout my tenure.

To all the members of the Leukaemia and Molecular Immunology Laboratories, thankyou for your friendships, and useful scientific and non-scientific communications. You made this a wonderful place in which to work and made my PhD experience more than tolerable.

To my parents, sister, and in-laws, thank you for your continuing support throughout this experience. I certainly could not have come this far without your help and encouragement and I love you all dearly.

Lastly, but certainly not least I wish to thank my husband, Don, the one person I have leant on continuously for support and without whom this would have been a far less enjoyable experience. I love you dearly and thank you for being my inspiration and motivation in life.

List of Figures

Figure 1.1	Schematic representation of haemopoiesis	3
Figure 1.2	Schematic of the Class I Cytokine Receptors	8
Figure 1.3	Overlapping motifs in the membrane-proximal region of cytokine receptors.	10
Figure 1.4	Schematic domain structure of JAK kinase	12
Figure 1.5	The JAK/STAT signal transduction pathway	17
Figure 1.6	Ras Signalling Cascade.....	22
Figure 1.7	Class IA PI3K domain structure.	29
Figure 1.9	Classification of SH3 recognition specificity	31
Figure 1.10	h β_c activating mutations.....	44
Figure 1.11	Summary of the effects on FDB1 cells of V449E and F1 Δ mutational analysis....	45
Figure 1.12	Summary of GMR signalling events.....	46
Figure 3.1	SH3-domain membrane array.	73
Figure 3.2	Fluorescence polarisation assay.....	76
Figure 3.3	GST pull-down assays.	78
Figure 3.4	hGMR α interacts with Lyn.....	80
Figure 3.5	hGMR α interacts with p85 and IKK β	82
Figure 3.6	Fluorescence polarisation assay.....	84
Figure 3.7	Unc119 expression profile.....	87
Figure 3.8	hUnc119-GST pull-downs.....	88
Figure 3.9	Schematic model for GMR α associated signalling and key downstream events. ...	94
Figure 4.1	Characterisation of FDB1 cell populations.....	102
Figure 4.2	Signalling properties of the h β_c mutants, F1 Δ and V449E.....	104
Figure 4.3	Activation of I κ B and AKT pathways is constitutive in the F1 Δ mutant.....	109
Figure 4.4	Sensitivity of FDB1 V449E to the JAK inhibitor AG490.	112
Figure 4.5	Sensitivity of FDB1 V449E to the JAK2 inhibitor JAK2 Inhibitor II.....	113
Figure 4.6	Sensitivity of FDB1 cell populations to MEK inhibitors U0126 and PD98059....	116
Figure 4.7	FDB1 V449E cell differentiation induced by MEK inhibition.....	119
Figure 4.8	Sensitivity of FDB1 F1 Δ to the PI3K inhibitors LY294002 and Wortmannin.	121
Figure 4.9	Schematic representation of GM-CSF receptor signalling and signalling by constitutive F1 Δ and V449E mutants	127

List of Tables

Table 1. Classification of Cytokines and their Receptors	6
Table 2. Heterogenous Biological Activities of IL-5, IL-3 and GM-CSF.....	35
Table 3. Known interactors of the GM-CSF receptor alpha subunit.....	39
Table 4. Specificity and mechanism of action of some commonly used inhibitors	99

List of Appendices

APPENDIX A Schematic of retroviral vector pRUFpuro	160
APPENDIX B Plasmid map of the glutathione S-transferase fusion vector, pGEX2T.	164
APPENDIX C Flow cytometric analysis of FDB1 cells populations stained with antibodies for phospho-STAT5A/B or p44/42 MAPK.	164
APPENDIX D Validation of AG490, JAK2 Inhibitor II, PD98059 and U0126 Inhibitors. ...	164
APPENDIX E Validation of LY294002 and Wortmannin Inhibitors.....	164

Abbreviations

aa	Amino acid
Ab	Antibody
Abs	Absorbance
ALL	Acute lymphoid leukaemia
AML	Acute myeloid leukaemia
bp	Base pairs
BM	Bone marrow
BSA	Bovine serum albumin
cDNA	Complementary DNA
DMEM	Dulbecco's modified eagle's medium
DMSO	Dimethyl sulphoxide
DNA	Deoxyribonucleic acid
dNTPs	Deoxyribonucleic acid triphosphates
E. coli	<i>Escherichia coli</i>
EDTA	Ethylenediamine tetra-acetate
EGTA	Ethyleneglycol-bis-(β -aminoethyl ether)- <i>N,N,N',N'</i> -tetraacetic acid
ERK	Extracellular regulated kinase
FACS	Fluorescence-Activated Cell Sorting
FBS	Fetal bovine serum
FITC	fluorescein isothiocyanate
g	Gram
GM-CSF	Granulocyte-macrophage colony-stimulating factor
GMR	Granulocyte-macrophage colony-stimulating factor receptor
GMR α	GMR alpha subunit
GST	Glutathione-S-transferase
h β_c	Human beta common
hr	Hour
HRP	Horse radish peroxidase
I κ B	I-kappa-B
IKK β	I-kappa-B kinase beta
IMDM	Iscove's modified Dulbecco's medium
IPTG	Isopropylthio-beta-D-galactosidase
JAK2	Janus kinase 2
kDa	Kilo Dalton

LB	Luria broth
M	Molar
MAPK	Mitogen-activated protein kinase
MEK	MAPK/ERK kinase
MFI	Mean fluorescence intensity
mg	Milligram
min	Minute
ml	Millilitre
mM	Millimolar
NFκB	Nuclear factor-kappa-B
OD	Optical density
PB	Peripheral blood
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PI3K	Phosphoinositol 3 kinase
RIPA	Radioimmunoprecipitation buffer
rpm	revolutions per minute
SDS	Sodium dodecyl sulphate
SDS-PAGE	Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SDM	Site-directed mutagenesis
STAT5	Signal transducer and activator of transcription 5
TEMED	N,N,N',N'-Tetramethylethylenediamine
μ	Micro (10 ⁻⁶)
μg	Micro gram
μL	Micro liter
μM	Micro molar
WCL	Whole cell lysate
WT	Wild-type
w/v	weight to volume

Abstract

Normal tissue homeostasis and appropriate responses to injury and infection are dependent on cellular communication mediated by cell surface receptors that respond to extrinsic stimuli. The GM-CSF receptor was the major focus of this project. This receptor shares a common signalling subunit, β_c , with the IL-3 and IL-5 receptors. The unique GM-CSF receptor α -subunit (GMR α) confers ligand binding specificity to the complex and is essential for GM-CSF receptor signalling, although the full complement of signalling events mediated by GMR α remains elusive. Through cloning of candidate interacting proteins, expression and co-immunoprecipitation studies, we have confirmed interactions for two proteins previously reported to interact with the GMR α , p85 and IKK β . Additionally, we identified the Src family kinase, Lyn, as a novel direct interacting partner of GMR α and provide insights into possible roles of this kinase in initiating signalling from the GM-CSF receptor. In addition to GMR α associated events we aimed to further characterise the role of the common β_c subunit in GM-CSF mediated signalling. We utilised two classes of constitutively active β_c mutants (extracellular or transmembrane) which transform the bi-potential myeloid FDB1 cell line to either factor-independent growth and survival, or granulocyte-macrophage differentiation, respectively. Here we report a comprehensive biochemical analysis of signalling by these two classes of mutants in this cell line. The two activated GMR mutants displayed distinct and non-overlapping signalling capacity. In particular, expression of a mutant with a substitution in the transmembrane domain (V449E) selectively activated JAK/STAT5 and MAPK pathways resulting in a high level of sensitivity to JAK and MEK inhibitors. In contrast, expression of a mutant with a 37

amino acid duplication in its extracellular domain (F1Δ) selectively activates the PI3K/AKT and IKKβ/NFκB pathways. Cells responding to this mutant display a relative high level of sensitivity to two independent PI3K inhibitors and relative resistance to inhibition of MEK and JAK2. The non-overlapping nature of signalling by these two activated mutants suggests that there are alternative modes of receptor activation that differentially dependent on JAK2 and that act synergistically in the mature liganded cytokine receptor complex. Further detailed analysis of these mutants will facilitate the dissection of the signalling pathways involved in the GM-CSF response that mediate proliferation, survival and differentiation.

Table of Contents

CHAPTER 1 - INTRODUCTION

1.1 Haemopoiesis	1
1.2 Growth Factors and their Receptors in Haemopoiesis	3
1.2.1 Receptor Tyrosine Kinases Involved in Haemopoiesis	3
1.2.2 Cytokine Receptor Structure and Classification.....	5
1.2.3 Cytokine Receptor Motifs Important in Receptor Signalling.....	9
1.3 Intracellular Signalling by Cytokine Receptors	11
1.3.1 Janus Kinase Structure and Function.....	11
1.3.2 Signal Transducers and Activators of Transcription	14
1.3.2.1 JAK2/STAT5 Signalling	16
1.3.2.2 Negative Regulators of JAK/STAT Signalling	17
1.3.3 JAKs in Haematological Malignancies	20
1.3.4 Ras Signalling.....	21
1.3.5 The PI3K/AKT Pathway	24
1.3.6 NF κ B Signalling.....	27
1.3.7 Src Family Kinases.....	28
1.3.7.1 Src-homology Domains.....	29
1.3.7.2 Signalling by Src Family Kinases.....	32
1.4 GM-CSF and its Receptor	34
1.4.1 GM-CSF Biology	34
1.4.2 GM-CSF Receptor Structure and Function	37
1.4.2.1 The GMR α Subunit.....	37
1.4.2.2 The β_c Subunit of GMR.....	41
1.4.3 GM-CSF Receptor Signalling Overview.....	44
1.5 Project Aims.....	47

CHAPTER 2 - MATERIALS AND METHODS

2.1 Materials	49
2.1.1 Oligonucleotide PCR Primers	52
2.2 Bacterial Techniques.....	52
2.2.1 Media and Solutions	52
2.2.2 Preparation of Chemically Competent E. coli.....	53
2.2.3 Midi-prep Plasmid Purification	54
2.2.4 Mini-prep Plasmid Purification	54
2.2.5 Transformation	55
2.3 Recombinant DNA Techniques.....	55

2.3.1	Restriction Digest and DNA ligation.....	55
2.3.2	PCR Amplification	56
2.3.3	Site Directed Mutagenesis	56
2.3.4	Sequencing	57
2.4	Tissue Culture.....	57
2.4.1	Media and Cytokines	57
2.4.2	Cell Lines and Maintenance	58
2.4.3	Transient Transfection of HEK293T Cells.....	58
2.4.4	Retroviral Transduction.....	59
2.5	Cell Viability Assays.....	60
2.6	Differentiation Assay.....	61
2.7	Immunoprecipitation and Western Blotting.....	61
2.7.1	Solutions and Buffers	61
2.7.2	Isolation of Protein from Cell Lines	62
2.7.3	Immunoprecipitation	63
2.7.4	SDS-PAGE Gel and Western Blotting	64
2.8	GST Pull-down	65
2.8.1	GST Fusion Protein Preparation.....	65
2.8.2	GST Pull-down.....	66
2.9	Fluorescence Polarisation	66
2.10	Intracellular Flow Cytometry	67
2.11	SH3 Membrane Domain Array.....	68
2.12	Statistical Analysis and Presentation of Data	68
 CHAPTER 3 – THE ROLE OF GMRα IN GM-CSF INDUCED SIGNALLING		
3.1	Introduction	69
3.2	Results – Characterisation of GMRα Interactions	71
3.2.1	Identification of Lyn and Src as Interacting Partners of GMR α	71
3.2.1.1	Identification of Novel Interactors of GMR α	72
3.2.1.2	Fluorescence Polarisation Confirms Binding of Lyn and Src SH3 Domains to mGMR α	74
3.2.1.3	GST pull-down confirms interaction of Lyn and Src SH3 domains to full-length hGMR α	77
3.2.1.4	Immunoprecipitations confirm the interaction between full-length Lyn and hGMR α 79	
3.2.2	Confirming Interactions of p85 and IKK β with hGMR α	81
3.2.2.1	Immunoprecipitations confirm interactions between endogenous p85 and IKK β with hGMR α	81
3.2.2.2	Nature of the interaction between p85 and hGMR α	83

3.2.3 The SFK Activator Unc119.....	85
3.2.3.1 Unc119 expression in myeloid cells.....	85
3.2.3.2 Unc119 Interactions.....	86
3.3 Discussion.....	89
 CHAPTER 4 - ACTIVATED MUTANTS LINK SIGNALLING PATHWAYS TO MYELOID CELL SURVIVAL	
4.1 Introduction.....	96
4.2 Results	99
4.2.1 Validation of the FDB1 Cell-Line Model.....	99
4.2.2 Differential Signalling Capacity of Constitutive F1Δ and V449E Mutants in FDB1 Cells 103	
4.2.3 F1Δ Constitutively Activates AKT and NFκB Pathways	107
4.2.4 JAK2 and MAPK Activity are Required for V449E Survival Signals while F1Δ Survival is Mediated by AKT/PI3K.....	108
4.2.4.1 Inhibition of JAK2 using Pharmacological Inhibitors.....	110
4.2.4.2 Inhibition of MAPK Signalling Using MEK Inhibitors	114
4.2.4.3 Inhibition of MAPK Instructs Differentiation of FDB1 V449E Cells.....	115
4.2.4.4 Inhibition of AKT Signalling using PI3K Inhibitors.....	118
4.3 Discussion.....	120
4.3.1 JAK-Independent Activation of Signalling from the F1Δ Mutant?	122
4.3.2 Key Survival Signals in F1Δ Include PI3K and NFκB?	123
4.3.3 Survival Signals in V449E	125
4.3.4 Summary.....	125
 CHAPTER 5 – DISCUSSION	
5.1 GMRα-Associated Signalling Events	129
5.2 βc-Associated Signalling Events	132
REFERENCES.....	136
APPENDICES.....	164